REVELATION BIOSCIENCES, INC. - 10-Q Filing
Revelation Biosciences filed a 10-Q for the quarter ended March 31, 2026, disclosing financial and operational details including expenses related to its GEM-AKI and GEM-CKD programs, manufacturing costs, and lease obligations. The filing also outlines equity incentive plans, warrant exercises, and stock-based compensation activities.
Tickers: $REVB